摘要
ObjectivesCirculating tumor (ct)DNA analysis is rapidly gaining acceptance as a diagnostic tool to guide clinical management of advanced non-small cell lung cancer (NSCLC). Clinically-actionable EGFR mutations can be detected in ctDNA before or after first-line EGFR-Tyrosine Kinase Inhibitor (TKI) treatment, but data are limited for patients with a complex treatment history. This study aimed to explore the feasibility of ctDNA testing in a clinical setting of NSCLC patients receiving osimertinib as a second or third line EGFR-TKI.Materials and MethodsTwenty EGFR T790M-positive NSCLC patients, who had received osimertinib as a second or third line EGFR-TKI and had donated blood samples while attending routine follow-up consultations between April and November 2016, were retrospectively selected to test plasma cfDNA for tumor-guided EGFR mutations. We used EGFR mutations previously identified in tumor-tissue to retrospectively test plasma ctDNA from 20 patients who had received osimertinib as a second or third line EGFR-TKI. Both EGFR-TKI sensitising and T790 M resistance mutations were analysed by droplet digital PCR (ddPCR) in plasma taken alongside routine consultations and ctDNA detection was correlated with response under osimertinib. Follow-up solid-tissue biopsies were obtained after disease progression.ResultsCtDNA was detected under osimertinib treatment in four out of the eight patients (50 %) who showed no response, two out of the seven (29 %) who showed an initial response and none of the five patients (0 %) who showed an ongoing response. The fraction of EGFR -mutant ctDNA in plasma tended to be higher in non-responders (0.1–68 %), compared to the initial responders (0.2–1.1 %). Blood samples were donated up to 34, 27 and 49 weeks after the start of osimertinib for the non-, initial and ongoing responders, respectively.ConclusionsThese findings support a potential role for ctDNA analysis in response monitoring of NSCLC patients with a complex EGFR-TKI treatment history. The weak trend between ctDNA detection and disease progression warrants larger studies to further investigate potential clinical utility.
学科与关键词
- Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patientsEva Boysen Fynboe Ebert; Tine McCulloch; Karin Holmskov Hansen; Hanne Linnet; Boe Sorensen; Peter Meldgaard2020.
- Serial plasma cell-free circulating tumor DNA tests identify genomic alterations for early prediction of osimertinib treatment outcome in EGFR T790M-positive non-small cell lung cancerBin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Ching-Yao Yang; Tzu-Hsiu Tsai; Wei-Yu Liao; Chao-Chi Ho; Chia-Chi Lin; Jin-Yuan Shih; Chong-Jen Yu; Ross A. Soo; James Chih-Hsin YangJTO Clinical and Research Reports, 2020, 100099.
- Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatmentProvencio Mariano; Serna-Blasco Roberto; Franco Fabio; Calvo Virgina; Royuela Ana; Auglytė Milda; Sánchez-Hernández Alfredo; de Julián Campayo María; García-Girón Carlos; Dómine Manuel; Blasco Ana; Sánchez José M.; Oramas Juana; Bosch-Barrera Joaquim; Sala María Á.; Sereno María; Ortega Ana L.; Chara Luis; Hernández Berta; Padilla Airam; Coves Juan; Blanco Remedios; Balsalobre José; Mielgo Xabier; Bueno Coralia; Jantus-Lewintre Eloisa; Molina-Vila Miguel Á.; Romero AtochaEuropean Journal of Cancer, 2021, 149.
